Peregrine Pharmaceuticals, Inc.( PPHM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Peregrine Pharmaceuticals, Inc.( PPHM)

PPHM 4.220

+0.7%

Jan 5 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Terry D. who started this subject	8/13/2003 10:48:14 AM
From: cjgaddy	Read Replies (1) of 3795

CHINA SDA LUNG Approval - Fav. Snippets 89.7% Disease Control Rate in Adv. Lung Cancer Patients The first radiolabeled monoclonal antibody approved for cancer therapy in China. Radiolabeled TNT provided significant patient benefit from the TNT therapy. All patients had failed prior therapies and had aggressive disease. "This initial approval represents a significant validation of the TNT technology for the treatment of cancer and the culmination of over a decade of research and development." (Dr. Epstein) "Given that there are no effective treatments for late stage lung cancer, there is a significant unmet need for new therapies in China and the rest of the world." (Dr. Epstein) "We view the approval of radiolabeled TNT in China along with the FDA acceptance of our TNT registration trial design as significant milestones in the development of TNT as a cancer treatment." said Steven King "We look forward to helping MediPharm develop its commercial manufacturing capabilities as it prepares for its market launch in China." (S.King) "We are very optimistic about the commercial potential of TNT in China." said Dian Wen Ju, MD, Ph.D., Senior VP of MediPharm Biotech. "We will continue with further clinical testing of TNT for other cancer indications. We are optimistic we will be able to file for additional TNT cancer indications with the Chinese SDA in the future, thus expanding the commercial potential of the drug." (Dian Wen Ju) TNT-based therapeutic agents have the potential to deliver therapeutic agents preferentially targeted to virtually all solid tumors. Given TNT's high specificity for necrotic tumor cells, TNT antibodies make excellent delivery molecules for a wide variety of anti-cancer killing agents. Medipharm also plans to start clinical testing in China of two new antibody based drugs in 2004.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next